scholarly journals Acute-onset Autoimmune Hepatitis in a Patient with Selective Immunoglobulin M Deficiency

2019 ◽  
Vol 58 (15) ◽  
pp. 2185-2190
Author(s):  
Akitoshi Sano ◽  
Jun Inoue ◽  
Eiji Kakazu ◽  
Masashi Ninomiya ◽  
Tomoaki Iwata ◽  
...  
2020 ◽  
Author(s):  
Kaoru Ueda ◽  
Yoshio Aizawa ◽  
Chika Kinoshita ◽  
Tomohisa Nagano ◽  
Jinya Ishida ◽  
...  

Abstract BACKGROUND Centrilobular zonal necrosis (CZN) is advocated as a histological hallmark present in a small number of patients with autoimmune hepatitis (CZN-AIH). Moreover, CZN has been detected in the absence of significant interface hepatitis, one of the most important histological findings of AIH. The concept of CZN-AIH as a distinctive subtype of AIH remains controversial, due to the rarity of CZN-AIH and the ambiguous definition of CZN. To elucidate the clinicopathological and immunogenetic features of CZN-AIH, and to evaluate the significance of co-existent interface hepatitis in CZN-AIH. METHODS A total of 102 biopsy samples of AIH, obtained at The Jikei University Katsushika Medical Center and Jikei University Hospital, were reviewed. The 32 patients whose biopsies showed CZN were selected as the CZN-AIH group and the remaining 70 were grouped as the non-CZN-AIH controls. In the CZN-AIH group, interface hepatitis was histologically present in 37.5% (n=12; mixed-type) and absent in 62.5% (n=20; pure-type). Data on clinical, histopathologic and immunogenetic features were statistically compared between the CZN-AIH group and the non-CZH-AIH controls. Additionally, significance of interface hepatitis in CZN-AIH was determined by comparative analysis of the mixed-type and pure-type subgroups. RESULTS Cases of CZN-AIH were more frequently of acute-onset hepatitis (56.2% vs chronic: 32.9%, P=0.031), lower immunoglobulin G level (P<0.001), lower antinuclear antibodies titer (P<0.001), and lower AIH score (P<0.001). Compared to the non-CZN-AIH cases, the CZN-AIH cases also tended to lack the typical histological characteristics of AIH and of the immunogenetic disproportionate distribution of HLA-DR genotypes in AIH (increased HLA-DR4 and decreased HLA-DR9), and responded more favorably to first-line therapy (P=0.054). For the acute-onset CZN-AIH cases, the clinical and histological features were indistinguishable from the non-acute cases. In contrast, the acute-onset non-CZN-AIH cases were distinguishable from the non-acute cases by lower antinuclear antibodies titer, lower immunoglobulin G level, and less advanced histological stage. The presence of interface hepatitis generally did not influence the morbidity of CZN-AIH, except for comorbid autoimmune diseases, higher gamma-glutamyltranspeptidase level, and increased immunoglobulin M level. CONCLUSION CZN-AIH is clinicopathologically and immunogenetically distinguishable. CZN can characterize a distinct AIH subtype, regardless of onset-pattern or co-existent interface hepatitis.


Kanzo ◽  
2013 ◽  
Vol 54 (11) ◽  
pp. 780-786
Author(s):  
Takashi Fushimi ◽  
Hironori Koga ◽  
Yutaka Kozuma ◽  
Teruko Arinaga-Hino ◽  
Takuji Torimura ◽  
...  

2004 ◽  
Vol 39 (7) ◽  
pp. 649-953 ◽  
Author(s):  
Yoshiyuki Suzuki ◽  
Mariko Kobayashi ◽  
Tetsuya Hosaka ◽  
Takashi Someya ◽  
Norio Akuta ◽  
...  

2020 ◽  
Vol 19 (1) ◽  
pp. 17-21 ◽  
Author(s):  
Vratislav Smolka ◽  
Oksana Tkachyk ◽  
Jiri Ehrmann ◽  
Eva Karaskova ◽  
Martin Zapalka ◽  
...  

2003 ◽  
Vol 42 (2) ◽  
pp. 158-162 ◽  
Author(s):  
Keiko KAWAI ◽  
Kojiro MICHITAKA ◽  
Shozo MIYAUCHI ◽  
Masahiro SANO ◽  
Masanori ABE ◽  
...  

2016 ◽  
Vol 28 (5) ◽  
pp. 607-608 ◽  
Author(s):  
Bulent Yilmaz ◽  
Ozan Unlu ◽  
Recep Evcen ◽  
Ceyhan Ugurluoglu

2021 ◽  
Vol 51 (2) ◽  
Author(s):  
María Laura Garrido ◽  
María Laura Reyes Toso ◽  
Sebastián Raffa ◽  
Valeria Inés Descalzi

We analyze the case of a 49-year-old male patient who presented with clinical signs of acute hepatitis with an initial suspicion of autoimmune etiology. Laboratory findings demonstrated positive antinuclear antibody, anti-smooth muscle antibody and high serum gamma globulin. Histology of the liver biopsy revealed changes compatible with autoimmune hepatitis, which associated with an International Autoimmune Hepatitis Group score of 7, determined the initiation of treatment with Meprednisolone and Azathioprine. During the follow-up, we received positive serological results of immunoglobulin M against hepatitis E virus with detectable viremia by reverse transcription polymerase chain reaction technique, changing the diagnosis to acute hepatitis secondary to hepatitis E virus. Immunosuppression was suspended and the patient continued with clinical and biochemical improvement. In Argentina, hepatitis E virus testing is not routinely performed, however, to avoid misdiagnosis, this etiology should be ruled out in patients with acute hepatitis before labeling it as autoimmune hepatitis. This could reduce unnecessary treatment that could endanger our patients.


2021 ◽  
Vol 27 (1) ◽  
pp. 58-69
Author(s):  
Atsumasa Komori

Autoimmune hepatitis (AIH) is an immunoinflammatory chronic liver disease with dynamic and rather heterogeneous disease manifestations. A trend of increasing prevalence of AIH has been observed worldwide, along with a relative increase in the percentage of male patients. AIH is characterized and diagnosed based on serum biochemistry and liver histology: elevated aminotransferases and serum immunoglobulin G (IgG), the presence of serum anti-nuclear antibody or anti-smooth muscle antibody, and interface lympho-plasmacytic hepatitis. Clinical manifestations differ among disease subtypes with distinct time-frames, i.e., AIH with a chronic insidious onset, and acute-onset AIH (the diagnosis of which is often challenging due to the lack of typical serum findings). The absence of disease-specific biomarkers or histological findings may expand the disease phenotype into drug-induced AIH-like liver injury. Corticosteroids and azathioprine are recommended first-line treatments for AIH. The complete normalization of aminotransferases and serum IgG is an essential treatment response to ensure long-term overall survival. An incomplete response or intolerance to these drugs is considered an indication for second-line treatment, especially with mycophenolate mofetil. Life-long maintenance treatment is required for the majority of patients, but the few who achieve prolonged and stringent biochemical remission with lower alanine aminotransferase and IgG within the normal range may be able to discontinue the medications. In the future, the quality of life of AIH patients should be managed by personalized medicine, including the appropriate selection and dosing of first-line therapy and perhaps alternating with potential therapeutics, and the prediction of the success of treatment withdrawal.


Kanzo ◽  
2008 ◽  
Vol 49 (5) ◽  
pp. 200-208 ◽  
Author(s):  
Mamiko Tsukui ◽  
Norio Isoda ◽  
Toshiya Otake ◽  
Toshihiko Higashisawa ◽  
Hiroyuki Osawa ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document